Moderna (NASDAQ:MRNA) Stock Price Down 8.2% – Should You Sell?

Moderna, Inc. (NASDAQ:MRNA)’s stock price fell 8.2% on Monday . The stock traded as low as $131.20 and last traded at $133.2460. Approximately 6,749,396 shares were traded during mid-day trading, a decline of 38% from the average session volume of 10,818,839 shares. The stock had previously closed at $145.13.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Positive Phase 3 cancer-vaccine data remains the main catalyst. Moderna and Merck reported that intismeran, used with Keytruda, met key goals in the INTerpath-001 study of resected melanoma. The result is viewed as an important validation of Moderna’s mRNA technology because it reportedly showed benefit over Keytruda alone—the first positive late-stage readout for an mRNA-based cancer vaccine in this setting. Moderna’s personalized cancer vaccine shows promise
• Positive Sentiment: Analysts see a substantial opportunity. Wolfe Research estimates the melanoma and broader cancer-vaccine opportunity could reach approximately $9.2 billion, while other analysts have raised ratings and highlighted the long-term potential of intismeran. That has helped shift the investment narrative beyond Moderna’s declining COVID-19 business. MRNA Stock Jumps Past $150
• Positive Sentiment: Broader mRNA validation is supporting sentiment. The FDA’s approval of the first mRNA-based flu vaccine could improve perceptions of mRNA platforms and reinforce the value of related intellectual property, although the approval is not itself a direct Moderna product catalyst. FDA Approves First mRNA-Based Flu Vaccine
• Neutral Sentiment: Trading momentum is amplifying the move. A reported “Power Inflow” signal and unusually heavy volume indicate strong buying interest, but these technical indicators do not establish the vaccine’s long-term commercial value. Moderna Shares Rise After Trading Signal
• Negative Sentiment: Investors face significant execution and valuation risks. The cancer-vaccine evidence remains limited, and broader adoption could be constrained by manufacturing complexity, regulatory requirements, cost, competition and the need for additional data. Analysts also caution that Moderna’s pipeline and financial outlook remain challenging outside this program. Explainer on the Merck-Moderna Cancer Vaccine
• Negative Sentiment: Profit-taking and geopolitical concerns could increase volatility. Moderna previously fell as traders locked in gains after its extraordinary advance. CEO Stéphane Bancel also warned that China is investing heavily in biotechnology and mRNA, creating a potential long-term competitive threat. Moderna CEO Warns About China’s mRNA Investment

Analyst Upgrades and Downgrades

Several research firms have commented on MRNA. Bank of America upgraded shares of Moderna from an “underperform” rating to a “neutral” rating in a research report on Wednesday, August 19th. William Blair upgraded Moderna from a “market perform” rating to an “outperform” rating in a research report on Wednesday, August 19th. Brookline Capital Markets reissued a “buy” rating on shares of Moderna in a report on Wednesday, August 19th. Jefferies Financial Group restated a “hold” rating on shares of Moderna in a research report on Wednesday, August 19th. Finally, The Goldman Sachs Group lifted their target price on Moderna from $67.00 to $120.00 and gave the company a “neutral” rating in a research note on Wednesday, August 19th. Four research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $74.31.

Moderna Stock Performance

The company’s 50-day moving average price is $72.29 and its two-hundred day moving average price is $57.69. The company has a market cap of $63.41 billion, a P/E ratio of -19.88 and a beta of 0.91. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09.

Moderna (NASDAQ:MRNA) last released its earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The business had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. During the same period in the previous year, the firm earned ($2.13) EPS. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. As a group, equities analysts forecast that Moderna, Inc. will post -6.18 earnings per share for the current year.

Insider Transactions at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 3,471 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the transaction, the insider directly owned 67,468 shares in the company, valued at $3,373,400. This trade represents a 4.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the transaction, the president directly owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. This trade represents a 3.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 10.80% of the company’s stock.

Hedge Funds Weigh In On Moderna

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. MUFG Securities EMEA plc purchased a new stake in shares of Moderna in the second quarter valued at $28,000. Allied Private Wealth LLC purchased a new stake in Moderna in the 2nd quarter worth about $30,000. Canton Hathaway LLC acquired a new stake in Moderna during the 1st quarter worth about $31,000. Archer Investment Corp purchased a new position in Moderna during the 2nd quarter valued at about $36,000. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Moderna by 148.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock valued at $37,000 after purchasing an additional 801 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.